Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-17 pm EDT			5-day change	1st Jan Change
25.58 ^USD	-0.16%		+8.16%	-6.02%

Aug. 06	Beam Therapeutics Shares Edge Higher Despite Wider Q2 Loss, Lower Revenue	MT
Aug. 06	Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024

August 06, 2024 at 06:30 am EDT

Beam Therapeutics Inc. reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported net loss was USD 91.05 million compared to USD 82.78 million a year ago. Basic loss per share from continuing operations was USD 1.11 compared to USD 1.08 a year ago. Diluted loss per share from continuing operations was USD 1.11 compared to USD 1.08 a year ago.
For the six months, net loss was USD 189.72 million compared to USD 179.24 million a year ago. Basic loss per share from continuing operations was USD 2.31 compared to USD 2.41 a year ago. Diluted loss per share from continuing operations was USD 2.31 compared to USD 2.41 a year ago.

Latest news about Beam Therapeutics Inc.

Beam Therapeutics Shares Edge Higher Despite Wider Q2 Loss, Lower Revenue	Aug. 06	MT
Beam Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Aug. 06	CI
Beam Therapeutics Shares Rise After HC Wainwright Starts Coverage at Buy	Jul. 23	MT
HC Wainwright Initiates Beam Therapeutics at Buy With $80 Price Target	Jul. 23	MT
Beam Therapeutics' Finance Chief Terry-Ann Burrell Leaving in August	Jul. 15	MT
Beam Therapeutics CFO Terry-Ann Burrell Departing in August	Jul. 15	MT
Beam Therapeutics Inc. Announces Resignation of Terry-Ann Burrell as Chief Financial Officer, Effective August 9, 2024	Jul. 15	CI
RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk	Jul. 09	MT
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 3000 Growth Index	Jun. 30	CI
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 3000E Growth Index	Jun. 30	CI
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 2000 Growth Index	Jun. 30	CI
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell 2500 Growth Index	Jun. 30	CI
Beam Therapeutics Inc.(NasdaqGS:BEAM) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Beam Therapeutics Insider Sold Shares Worth $1,470,156, According to a Recent SEC Filing	Jun. 28	MT
Beam Therapeutics Inc. Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency	Jun. 26	CI
Beam Therapeutics Inc. Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease	Jun. 14	CI
Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates	May. 07	MT
Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Beam Therapeutics Insider Sold Shares Worth $581,617, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Insider Sold Shares Worth $734,805, According to a Recent SEC Filing	Apr. 04	MT
Beam Therapeutics Says BEAM-302 Drug Candidate Gets UK Clearance for Alpha-1 Antitrypsin Deficiency	Mar. 26	MT
Beam Therapeutics Inc. Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency	Mar. 26	CI
Transcript : Beam Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:35 PM	Mar. 13
Barclays Raises Price Target on Beam Therapeutics to $42 From $26, Maintains Equalweight Rating	Feb. 28	MT
RBC Raises Price Target on Beam Therapeutics to $35 From $27 on 'More Favorable Regulatory Environment,' Keeps Sector Perform, Speculative Risk	Feb. 28	MT

Chart Beam Therapeutics Inc.

Duration

Period

More charts

Company Profile

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Employees

461

Sector

Biotechnology & Medical Research

Calendar

2024-11-03 - Q3 2024 Earnings Release (Projected)

More about the company